Posts Tagged: AstraZeneca
I’m not defending what Novartis did or trying to find an excuse for the company. It violated the FCPA, and (along with a former subsidiary) paid nearly $347 million in penalties and disgorgement to resolve the offenses.… Continue Reading
Pharmaceuticals companies continue to fall foul of the FCPA and other anti-bribery laws, with a number of 2016 cases suggesting a vulnerability around marketing practices especially in the Asia-Pacific region. Why does a sector that is way ahead of the compliance game in so many ways keep getting caught out by anti-bribery laws?… Continue Reading
The Securities and Exchange Commission Tuesday charged U.K.-based pharma AstraZeneca PLC with violating the books and records and internal controls provisions of the Foreign Corrupt Practices Act when wholly-owned subsidiaries in China and Russia made illegal payments to boost drug sales.… Continue Reading
Pharma AstraZeneca LP agreed to pay $7.9 million to settle allegations that it violated the False Claims Act by paying kickbacks to sell its drugs, the DOJ said.
AstraZeneca markets and sells pharmaceutical products in the United States, including a drug sold under the trade name Nexium.… Continue Reading
A police investigation in China has found that drugmaker GlaxoSmithKline’s alleged bribery of doctors ‘was coordinated by the British company and was not the work of individual employees,’ according to a report Tuesday by Reuters.… Continue Reading
Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.
“It is rumored that police in plain clothes are patrolling in hospitals; drug sales representatives will be fined 500 yuan ($81) and regional sales managers 1000 yuan ($162) once being caught in hospitals,” an unidentified sales representative told the paper.… Continue Reading
China state media reported Saturday that French drugmaker Sanofi SA is under investigation for allegedly bribing doctors to increase sales.
Here are the first four items:
… Continue Reading
China: Glaxo Executive Says Changes in China to Cut Drug Prices
Published on Jul 24, 2013 03:00 am
GlaxoSmithKline Plc (GSK)’s head of emerging markets said after meeting with government officials in Beijing some employees may have broken China’s laws and pledged corporate changes that will deliver cheaper medicines.